Abstract
Interleukin-15 is a pleotropic factor, capable of modulating metabolism, survival, proliferation, and differentiation in many different cell types. The rationale behind this study relates to previous work demonstrating that IL-15 is a major factor present in stem cell extracts, which protects cardiomyocytes subjected to hypoxic stress in vitro. The objective of this current study was to assess whether administration of IL-15 peptide will also show protective effects in vivo. The data indicate that administration of IL-15 reduces cell death, increases vascularity, decreases scar size, and significantly improves left ventricular ejection fraction in a mouse model of myocardial infarction.
Publication types
-
Research Support, N.I.H., Extramural
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Animals
-
Cardiovascular Agents / pharmacology*
-
Cell Death / drug effects
-
Cells, Cultured
-
Disease Models, Animal
-
Human Umbilical Vein Endothelial Cells / drug effects
-
Humans
-
Interleukin-15 / pharmacology*
-
Male
-
Mice, Inbred C57BL
-
Myocardial Infarction / drug therapy*
-
Myocardial Infarction / pathology
-
Myocardial Infarction / physiopathology
-
Myocytes, Cardiac / drug effects*
-
Myocytes, Cardiac / pathology
-
Neovascularization, Physiologic / drug effects
-
Recovery of Function
-
Stroke Volume / drug effects*
-
Ventricular Function, Left / drug effects*
Substances
-
Cardiovascular Agents
-
Interleukin-15